Document:

exv4w3

 

Exhibit 4.3

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO
THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR
HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN
THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES,
SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.

WARRANT TO PURCHASE STOCK

Company: Hansen Medical, Inc., a Delaware corporation

Number of Shares: [___] [insert number of shares equal to: (a) ___% multiplied by the total
dollar amount of the relevant Growth Capital Advance (both SVB’s and Gold Hill’s portion), divided
by (b) $1.40]

Class of Stock: Series B Preferred

Warrant Price: $1.40 per share

Issue Date: [                     ___,] 2005 [insert relevant Growth Capital Advance Funding Date]

Expiration Date: [                     ___,] 2010 [insert date 5 years after relevant Growth Capital Advance
Funding Date]

     THIS WARRANT CERTIFIES THAT, for the agreed upon value of $1.00 and for other good and
valuable consideration, including without limitation the mutual promises contained in that certain
Joint Loan and Security Agreement of even date herewith (the “Loan Agreement”) entered into by and
among SILICON VALLEY BANK (“Holder”), Gold Hill Venture Lending 03, LP and the company named above
(the “Company”), Holder is entitled to purchase the number of fully paid and nonassessable shares
of the Class of Stock (the “Shares”) of the Company at the Warrant Price, all as set forth above
and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions and upon the terms
and conditions set forth in this Warrant. This Warrant is issued in connection with the Loan
Agreement.

ARTICLE 1 EXERCISE.

     1.1 Method of Exercise. Holder may exercise this Warrant by delivering a duly
executed Notice of Exercise in substantially the form attached as Appendix 1 and this Warrant to
the principal office of the Company. Unless Holder is exercising the conversion right set forth in
Article 1.2, Holder shall also deliver to the Company a check, wire transfer (to an account
designated by the Company), or other form of payment acceptable to the Company for the aggregate
Warrant Price for the Shares being purchased.

     1.2 Conversion Right. In lieu of exercising this Warrant as specified in Article 1.1,
if the fair market value of the Shares is greater than the Warrant Price, Holder may elect to
receive shares equal to the value (as determined below) of this Warrant (or the portion thereof
being exercised) by surrender of this Warrant at the principal office of the Company together with
a duly executed Notice of Exercise, in which event the Company shall issue to Holder a number of

1.

 

shares of Series B Preferred Stock computed using the following formula (and, if applicable, a
new warrant evidencing the balance of the shares remaining subject to this Warrant):

	 	 	 	 	 
	X=

	 	Y(A-B)
 

A
	 	 

	 	 	 	 	 
	Where:

	 	X =
	 	the number of shares of Series B Preferred Stock to be issued to Holder
	 
	 	 	 	 
	 

	 	Y =
	 	the number of shares of Series B Preferred Stock purchasable under the
Warrant or, if only a portion of the Warrant is being exercised, the portion of the
Warrant being exercised
	 
	 	 	 	 
	 

	 	A =
	 	the fair market value of one share of the Company’s Series B Preferred Stock
	 
	 	 	 	 
	 

	 	B =
	 	the Warrant Price, as adjusted

The fair market value of the Shares shall be determined pursuant to Article 1.3.

     1.3 Fair Market Value. If the Company’s common stock is traded in a public market and
the Shares are common stock, the fair market value of each Share shall be the closing price of a
Share reported for the business day immediately before Holder delivers its Notice of Exercise to
the Company (or in the instance where the Warrant is exercised immediately prior to the
effectiveness of the Company’s initial public offering, the “price to public” per share price
specified in the final prospectus relating to such offering). If the Company’s common stock is
traded in a public market and the Shares are preferred stock, the fair market value of a Share
shall be the closing price of a share of the Company’s common stock reported for the business day
immediately before Holder delivers its Notice of Exercise to the Company (or, in the instance where
the Warrant is exercised immediately prior to the effectiveness of the Company’s initial public
offering, the initial “price to public” per share price specified in the final prospectus relating
to such offering), in both cases, multiplied by the number of shares of the Company’s common stock
into which a Share is convertible. If the Company’s common stock is not traded in a public market,
the Board of Directors of the Company shall determine fair market value in its reasonable good
faith judgment.

     1.4 Delivery of Certificate and New Warrant. Promptly after Holder exercises or
converts this Warrant and, if applicable, the Company receives payment of the aggregate Warrant
Price, the Company shall deliver to Holder a certificate or certificates for the Shares acquired
and, if this Warrant has not been fully exercised or converted and has not expired, a new Warrant
representing the Shares not so acquired.

     1.5 Replacement of Warrants. On receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss,
theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and
amount to the Company or, in the case of mutilation on surrender and cancellation of this Warrant,
the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

2.

 

     1.6 Treatment of Warrant Upon Acquisition of Company.

          1.6.1 “Acquisition”. For the purpose of this Warrant, “Acquisition” means (a) any
consolidation or merger of the Company with or into any other corporation or other entity or
person, or any other corporate reorganization, in which the stockholders of the Company immediately
prior to such consolidation, merger or reorganization, own less than 50% of the voting power of the
surviving entity immediately after such consolidation, merger or reorganization; (b) any
transaction or series of related transactions to which the Company is a party in which in excess of
fifty percent (50%) of the Company’s voting power is transferred provided that an Acquisition shall
not include (x) any consolidation or merger effected exclusively to change the domicile of the
Company or (y) any transaction or series of transactions principally for bona fide equity financing
purposes in which cash is received by the Company or indebtedness of the Company is cancelled or
converted or a combination thereof; or (c) a sale, lease, or other disposition of all or
substantially all of the assets of the Company.

          1.6.2 Treatment of Warrant at Acquisition.

A) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that
is not an asset sale and in which the sole consideration is cash, either (a) Holder shall exercise
its conversion or purchase right under this Warrant and such exercise will be deemed effective
immediately prior to the consummation of such Acquisition or (b) if Holder elects not to exercise
the Warrant, this Warrant will expire upon the consummation of such Acquisition. The Company shall
provide the Holder with written notice of its request relating to the foregoing (together with such
reasonable information as the Holder may request in connection with such contemplated Acquisition
giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior
to the closing of the proposed Acquisition.

B) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that
is an “arms length” sale of all or substantially all of the Company’s assets (and only its assets)
to a third party that is not an Affiliate (as defined below) of the Company (a “True Asset Sale”),
either (a) Holder shall exercise its conversion or purchase right under this Warrant and such
exercise will be deemed effective immediately prior to the consummation of such Acquisition or (b)
if Holder elects not to exercise the Warrant, this Warrant will continue until the Expiration Date
if the Company continues as a going concern following the closing of any such True Asset Sale. The
Company shall provide the Holder with written notice of its request relating to the foregoing
(together with such reasonable information as the Holder may request in connection with such
contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less
than ten (10) days prior to the closing of the proposed Acquisition.

C) Upon the written request of the Company, Holder agrees that, in the event of a Acquisition of
the Company by a publicly traded acquirer for either a combination of cash and shares or shares
only of the publicly traded company, if, on the record date for the Acquisition, the fair market
value of the Shares (or other securities issuable upon exercise of this Warrant) is equal to or
greater than three (3) times the Warrant Price, either (a) Holder shall exercise its conversion or
purchase right under this Warrant and such exercise will be deemed effective immediately prior to
the consummation of such Acquisition and the Holder shall participate in

3.

 

the Acquisition as a holder of the Shares (or other securities issuable upon exercise of the
Warrant) on the same terms as other holders of the same class of securities of the Company, or (b)
if Holder elects not to exercise the Warrant, this Warrant will expire upon the consummation of
such Acquisition.

D) In the event of any Acquisition other than those particularly described in subsections (A), (B)
or (C) above, the successor entity shall assume the obligations of this Warrant, and this Warrant
shall be exercisable for the same securities, cash, and property as would be payable for the Shares
issuable upon exercise of the unexercised portion of this Warrant as if such Shares were
outstanding on the record date for the Acquisition and subsequent closing (the Warrant Price and/or
number of Shares shall be adjusted accordingly); provided, however, that if the consideration to be
received by Holder for each Share in such Acquisition (assuming exercise of the Warrant) equals or
exceeds three (3) times the Warrant Price, this Warrant shall automatically be exercised pursuant
to Section 1.1 or 1.2 above, at Holder’s option, immediately prior to such Acquisition. The
Company shall provide the Holder with written notice of the Acquisition (together with such
reasonable information as the holder may request in connection with such contemplated Acquisition
giving rise to such notice) and automatic exercise, if applicable, not less than ten (10) days
prior to the closing of the proposed Acquisition. If the consideration to be received by Holder in
the Acquisition is less than three (3) times the Warrant Price for each Share, the Company may, at
its sole election, pay Holder a sum equal to two (2) times the Warrant Price for each Share
exercisable hereunder in exchange for the cancellation of this Warrant prior to or upon the
consummation of the Acquisition.

As used herein “Affiliate” shall mean any person or entity that owns or controls directly or
indirectly ten (10) percent or more of the stock of Company, any person or entity that controls or
is controlled by or is under common control with such persons or entities, and each of such
person’s or entity’s officers, directors, joint venturers or partners, as applicable.

ARTICLE 2 ADJUSTMENTS TO THE SHARES.

     2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on the
Shares payable in common stock, or other securities, then upon exercise of this Warrant, for each
Share acquired, Holder shall receive, without cost to Holder, the total number and kind of
securities to which Holder would have been entitled had Holder owned the Shares of record as of the
date the dividend occurred. If the Company subdivides the Shares by reclassification or otherwise
into a greater number of shares or takes any other action which increase the amount of stock into
which the Shares are convertible, the number of shares purchasable hereunder shall be
proportionately increased and the Warrant Price shall be proportionately decreased. If the
outstanding shares are combined or consolidated, by reclassification or otherwise, into a lesser
number of shares, the Warrant Price shall be proportionately increased and the number of Shares
shall be proportionately decreased.

     2.2 Reclassification, Exchange, Combinations or Substitution. Upon any
reclassification, exchange, substitution, or other event that results in a change of the number
and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall
be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of
securities and property that Holder would have received for the Shares if this Warrant had been

4.

 

exercised immediately before such reclassification, exchange, substitution, or other event.
Such an event shall include any automatic conversion of the outstanding or issuable securities of
the Company of the same class or series as the Shares to common stock pursuant to the terms of the
Company’s Certificate of Incorporation upon the closing of a registered public offering of the
Company’s common stock. The Company or its successor shall promptly issue to Holder an amendment
to this Warrant setting forth the number and kind of such new securities or other property issuable
upon exercise or conversion of this Warrant as a result of such reclassification, exchange,
substitution or other event that results in a change of the number and/or class of securities
issuable upon exercise or conversion of this Warrant (provided that if the amendment to this
Warrant is actually an amended and restated warrant, then Holder shall be required to return this
original Warrant to the Company to exchange for the amended and restated warrant). The amendment
to this Warrant shall provide for adjustments which shall be as nearly equivalent as may be
practicable to the adjustments provided for in this Article 2 including, without limitation,
adjustments to the Warrant Price and to the number of securities or property issuable upon exercise
of the new Warrant. The provisions of this Article 2.2 shall similarly apply to successive
reclassifications, exchanges, substitutions, or other events.

     2.3 Adjustments for Diluting Issuances. The Warrant Price and the number of Shares
issuable upon exercise of this Warrant or, if the Shares are preferred stock, the number of shares
of common stock issuable upon conversion of the Shares, shall be subject to adjustment, from time
to time in the manner set forth in the Company’s Certificate of Incorporation as if the Shares were
issued and outstanding on and as of the date of any such required adjustment. The provisions set
forth in the Company’s Certificate of Incorporation in effect as of the Issue Date for the series
and class of stock which the Shares consist may not be amended, modified or waived, without the
prior written consent of Holder, unless such amendment, modification or waiver affects each share
of such series or class of stock in the same manner other than with respect to any difference in
the original issue price of such shares.

     2.4 No Impairment. The Company shall not, by amendment of its Articles or Certificate
(as applicable) of Incorporation or through a reorganization, transfer of assets, consolidation,
merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to
avoid the observance or performance of any of the terms to be observed or performed under this
Warrant by the Company, but shall at all times in good faith assist in carrying out of all the
provisions of this Article 2 and in taking all such action as may be necessary or appropriate to
protect Holder’s rights under this Article against impairment. Notwithstanding the foregoing,
nothing in this Section 2.4 shall prohibit the Company from amending its Certificate of
Incorporation with the requisite consent of the stockholders and the Board of Directors so long as
such amendment affects the rights granted to Holder associated with the Shares in the same manner
as the other holders of Series B Preferred Stock other than with respect to any difference in the
original issue price of such shares.

     2.5 Fractional Shares. No fractional Shares shall be issuable upon exercise or
conversion of this Warrant and the number of Shares to be issued shall be rounded down to the
nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the
Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount
computed by multiplying the fractional interest by the fair market value of a full Share.

5.

 

     2.6 Certificate as to Adjustments. Upon each adjustment of the Warrant Price, the
Company shall promptly notify Holder in writing, and, at the Company’s expense, promptly compute
such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth
such adjustment and the facts upon which such adjustment is based. The Company shall, upon written
request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date
thereof and the series of adjustments leading to such Warrant Price.

ARTICLE 3 REPRESENTATIONS AND COVENANTS OF THE COMPANY.

     3.1 Representations and Warranties. The Company represents and warrants to the Holder
as follows:

          (a) The initial Warrant Price referenced on the first page of this Warrant is not greater than
the price per share at which the Company’s Series B Preferred Stock were last issued in an
arms-length transaction in which at least $500,000 of the Shares were sold.

          (b) All Shares which may be issued upon the exercise of the purchase right represented by this
Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance,
be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and
encumbrances except for restrictions on transfer provided for herein or under applicable federal
and state securities laws.

          (c) The Company further covenants and agrees that, during the period within which the rights
represented by this Warrant may be exercised, the Company will at all times have authorized and
reserved for the purpose of issue or transfer upon exercise of the subscription rights evidenced by
this Warrant, a sufficient number of Shares of authorized but unissued stock, or other securities
and property, when and as required to provide for the exercise of the rights represented by this
Warrant.

     3.2 Notice of Certain Events. If the Company proposes at any time (a) to declare any
dividend or distribution upon any of its stock, whether in cash, property, stock, or other
securities and whether or not a regular cash dividend; (b) to effect any reclassification or
recapitalization of any of its stock; (c) to merge or consolidate with or into any other
corporation, or sell, lease, license, or convey all or substantially all of its assets, or to
liquidate, dissolve or wind up; or (d) offer holders of registration rights the opportunity to
participate in an underwritten public offering of the Company’s securities for cash, then, in
connection with each such event, the Company shall give Holder: (1) at least 10 days prior written
notice of the date on which a record will be taken for such dividend, distribution, or subscription
rights (and specifying the date on which the holders of common stock will be entitled thereto) or
for determining rights to vote, if any, in respect of the matters referred to in (b) and (c) above;
(2) in the case of the matters referred to in (b) and (c) above at least 10 days prior written
notice of the date when the same will take place (and specifying the date on which the holders of
common stock will be entitled to exchange their common stock for securities or other property
deliverable upon the occurrence of such event); and (3) in the case of the matter referred to in
(d) above, the same notice as is given to the holders of such registration rights. The Company
shall send a concurrent written notice to Holder if the Company sends any written notice to its
preferred stockholders regarding the Company offering for sale any shares of the Company’s capital
stock (or other securities

6.

 

convertible into such capital stock), other than (i) pursuant to the Company’s stock option or
other compensatory plans, (ii) in connection with commercial credit arrangements or equipment
financings, or (iii) in connection with strategic transactions for purposes other than capital
raising.

     3.3 Registration Under Securities Act of 1933, as amended. The Company agrees that
the Shares or, if the Shares are convertible into common stock of the Company, such common stock,
shall have certain incidental, or “Piggyback,” registration rights pursuant to and as set forth in
the Company’s Amended and Restated Investor Rights Agreement dated as of May 21, 2004 (the
“Investor Rights Agreement”) as it may be amended from time to time or similar agreement.
The Company will use its best efforts to amend such agreement within sixty (60) days of the Issue
Date such that Holder shall become a party to the Investor Rights Agreement for the purposes of
this Section 3.3; provided that if Section 5.3 or Section 5.4 of this Warrant conflicts with any
provisions of the Investor Rights Agreement, the provisions of Section 5.3 or Section 5.4 of this
Warrant, as applicable, shall control until this Warrant has been fully exercised or terminated.
The provisions set forth in the Company’s Investor Rights Agreement or similar agreement relating
to the above in effect following such amendment may not be amended, modified or waived without the
prior written consent of Holder unless such amendment, modification or waiver affects the rights
associated with the Shares in the same manner as such amendment, modification, or waiver affects
the rights associated with all other shares of the same series and class as the Shares granted to
the Holder other than with respect to any difference in the original issue price of such shares.

     3.4 No Shareholder Rights. Except as provided in this Warrant, the Holder will not
have any rights as a shareholder of the Company until the exercise of this Warrant.

ARTICLE 4 REPRESENTATIONS, WARRANTIES OF THE HOLDER. The Holder represents and warrants to
the Company as follows:

     4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon
exercise of this Warrant by the Holder will be acquired for investment for the Holder’s account,
not as a nominee or agent, and not with a view to the public resale or distribution within the
meaning of the Act. Holder also represents that the Holder has not been formed for the specific
purpose of acquiring this Warrant or the Shares.

     4.2 Disclosure of Information. The Holder has received or has had full access to all
the information it considers necessary or appropriate to make an informed investment decision with
respect to the acquisition of this Warrant and its underlying securities. The Holder further has
had an opportunity to ask questions and receive answers from the Company regarding the terms and
conditions of the offering of this Warrant and its underlying securities and to obtain additional
information (to the extent the Company possessed such information or could acquire it without
unreasonable effort or expense) necessary to verify any information furnished to the Holder or to
which the Holder has access.

     4.3 Investment Experience. The Holder understands that the purchase of this Warrant
and its underlying securities involves substantial risk. The Holder has experience as an investor
in securities of companies in the development stage and acknowledges that the Holder can bear

7.

 

the economic risk of such Holder’s investment in this Warrant and its underlying securities
and has such knowledge and experience in financial or business matters that the Holder is capable
of evaluating the merits and risks of its investment in this Warrant and its underlying securities
and/or has a preexisting personal or business relationship with the Company and certain of its
officers, directors or controlling persons of a nature and duration that enables the Holder to be
aware of the character, business acumen and financial circumstances of such persons.

     4.4 Accredited Investor Status. The Holder is an “accredited investor” within the
meaning of Regulation D promulgated under the Act.

     4.5 The Act. The Holder understands that this Warrant and the Shares issuable upon
exercise or conversion hereof have not been registered under the Act in reliance upon a specific
exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the
Holder’s investment intent as expressed herein. The Holder understands that this Warrant and the
Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently
registered under the Act and qualified under applicable state securities laws, or unless exemption
from such registration and qualification are otherwise available.

ARTICLE 5 MISCELLANEOUS.

     5.1 Term: This Warrant is exercisable in whole or in part at any time and from time to
time on or before the Expiration Date.

     5.2 Legends. This Warrant and the Shares (and the securities issuable, directly or
indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in
substantially the following form:

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE
AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED,
SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED
UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL
COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH
OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.

     5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable
upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion
of the Shares, if any) may not be transferred or assigned in whole or in part without compliance
with applicable federal and state securities laws by the transferor and the transferee (including,
without limitation, the delivery of investment representation letters and legal opinions reasonably
satisfactory to the Company, as reasonably requested by the Company) and the transferee agrees to
be bound by all of the terms and conditions of this Warrant. The Company shall not require Holder
to provide an opinion of counsel if the transfer is to (a) Holder’s parent

8.

 

company, SVB Financial Group (formerly Silicon Valley Bancshares), or (b) any other affiliate
of Holder provided that Holder provides the Company with appropriate documentation of such entity’s
affiliate status. Additionally, the Company shall also not require an opinion of counsel if there
is no material question as to the availability of current information as referenced in Rule 144(c),
Holder represents that it has complied with Rule 144(d) and (e) in reasonable detail, the selling
broker represents that it has complied with Rule 144(f), and the Company is provided with a copy of
Holder’s notice of proposed sale.

     5.4 Transfer Procedure. Upon receipt by Holder of the executed Warrant, Holder will
transfer all of this Warrant to Holder’s parent company, SVB Financial Group, by execution of an
Assignment substantially in the form of Appendix 2 whereby the transferee agrees to be bound by all
of the obligations of Holder under this Warrant. Subject to the provisions of Article 5.3 and upon
providing Company with written notice, SVB Financial Group and any subsequent Holder may transfer
all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the Shares
issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee,
provided, however, in connection with any such transfer, SVB Financial Group or any subsequent
Holder will give the Company notice of the portion of the Warrant being transferred with the name,
address and taxpayer identification number of the transferee and Holder will surrender this Warrant
to the Company for reissuance to the transferee(s) (and Holder if applicable) by execution of an
Assignment substantially in the form of Appendix 2 whereby the transferee agrees to be bound by all
of the obligations of Holder under this Warrant. The Company may refuse to transfer this Warrant
or the Shares to any person who directly competes with the Company, unless, in either case, the
stock of the Company is publicly traded. Notwithstanding anything herein to the contrary, except
for Silicon Valley Bank’s transfer of this Warrant to SVB Financial Group, the Company will not be
obligated to effect any transfer of all or any portion of this Warrant or the Shares held by Holder
if such disposition would require the Company to register securities pursuant to Section 12(g) of
the Securities Exchange Act of 1934, as amended.

     5.5 Notices. All notices and other communications from the Company to the Holder, or
vice versa, shall be deemed delivered and effective when given personally or mailed by first-class
registered or certified mail, postage prepaid, at such address as may have been furnished to the
Company or the Holder, as the case may (or on the first business day after transmission by
facsimile) be, in writing by the Company or such Holder from time to time. Effective upon receipt
of the fully executed Warrant and the initial transfer described in Article 5.4 above, all notices
to the Holder shall be addressed as follows until the Company receives notice of a change of
address in connection with a transfer or otherwise:

SVB Financial Group

Attn: Treasury Department

3003 Tasman Drive, HA 200

Santa Clara, CA 95054

Telephone: 408-654-7400

Facsimile: 408-496-2405

Notice to the Company shall be addressed as follows until the Holder receives notice of a change in
address:

9.

 

Hansen Medical, Inc.

Attn: Larry J. Strauss, Chief Financial Officer

380 North Bernardo Avenue

Mountain View, CA 94043

Telephone: (650) 404-5800

Facsimile: (650) 404-5901

     5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or
terminated only by an instrument in writing signed by the party against which enforcement of such
change, waiver, discharge or termination is sought.

     5.7 Attorney’s Fees. In the event of any dispute between the parties concerning the
terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to
collect from the other party all costs incurred in such dispute, including reasonable attorney’s
fees.

     5.8 Automatic Conversion upon Expiration. In the event that, upon the Expiration
Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as
determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such
date, then this Warrant shall automatically be deemed on and as of such date to be converted
pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not
previously have been exercised or converted, and the Company shall promptly deliver a certificate
representing the Shares (or such other securities) issued upon such conversion to the Holder.

     5.9 Counterparts. This Warrant may be executed in counterparts, all of which together
shall constitute one and the same agreement.

     5.10 Governing Law. This Warrant shall be governed by and construed in accordance
with the laws of the State of California, without giving effect to its principles regarding
conflicts of law.

     5.11 Market Stand-Off. The Holder and any permitted transferee agree to be bound by
the “Market Stand-Off” provision in Section 1.13 of the Company’s Investor Rights Agreement as it
may be amended from time to time; provided, however, the Market Stand-Off provision set forth in
the Investor Rights Agreement in effect as of the Issue Date for the series and class of stock
which the Shares consist may not be amended, modified or waived, without the prior written consent
of Holder, unless such amendment, modification or waiver affects each share of such series or class
of stock in the same manner other than with respect to any difference in the original issue price
of such shares.

[Remainder of page intentionally left blank; signature page follows)

10.

 

In Witness Whereof, the Company has caused this Warrant to be executed by its duty authorized
officer as of the Issue Date.

	 	 	 	 	 
	“COMPANY”	 	 
	 
	 	 	 	 
	HANSEN MEDICAL, INC.	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	 

	 	 

	 	 
	Name:

	 	Frederic H. Moll, M.D., Ph.D.	 	 
	 
	 	 	 	 
	Title:

	 	President and Chief Executive Officer	 	 
	 
	 	 	 	 
	Agreed and Accepted:	 	 
	 
	 	 	 	 
	“HOLDER”	 	 
	 
	 	 	 	 
	SILICON VALLEY BANK	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	 

	 	 

	 	 
	Name:
	 	 	 	 
	 

	 	 

(Print)
	 	 
	Title:
	 	 	 	 
	 

	 	 

	 	 

11.

 

APPENDIX 1

NOTICE OF EXERCISE

     1. Holder
elects to purchase                      shares of the Common/Series ___ Preferred
[strike one] Stock of                                          pursuant to the terms of the attached Warrant, and tenders
payment of the purchase price of the shares in full.

          [or]

     1. Holder elects to convert the attached Warrant into Shares/cash [strike one] in the manner
specified in the Warrant. This conversion is exercised for                                          of the Shares
covered by the Warrant

          [Strike paragraph that does not apply.]

     2. Please issue a certificate or certificates representing the shares in the name specified
below: .

	 	 	 	 	 
	 

	 	 

               Holders Name
	 	 
	 
	 	 	 	 
	 

	 	 

	 	 
	 

	 	 

               (Address)
	 	 

     3. By its execution below and for the benefit of the Company, Holder hereby restates each of
the representations and warranties in Article 4 of the Warrant as the date hereof.

	 	 	 	 	 	 	 
	 	 	HOLDER:	 	 
	 
	 	 	 	 	 	 
	 

	 	 

	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Date:	 	 	 	 
	 

	 	 	 	 

	 	 

12.

 

APPENDIX 2

ASSIGNMENT

For value received, Silicon Valley Bank hereby sells, assigns and transfers unto

	 	 	 
	Name:

	 	SVB Financial Group
	Address:

	 	3003 Tasman Drive (HA-200)
	 

	 	Santa Clara, CA 95054
	Tax ID:

	 	91-1962278

that certain Warrant to Purchase Stock issued by Hansen Medical, Inc. (the
“Company’), on                                          (the “Warrant’) together with all rights, title and
interest therein.

	 	 	 	 	 	 	 	 	 
	 	 	 	 	SILICON VALLEY BANK	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 
	 

	 	 	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 
	 

	 	 	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 
	Date:
	 	 	 	 	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

By its execution below, and for the benefit of the Company, SVB Financial Group makes each of the
representations and warranties set forth in Article 4 of the Warrant and agrees to all other
provisions of the Warrant as of the date hereof.

	 	 	 	 	 	 	 	 	 
	 	 	 	 	SVB FINANCIAL GROUP	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 
	 

	 	 	 	Name:	 	 	 	 
	 

	 	 
	 	 	 	 

	 	 
	 

	 	 	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 

13.exv4w4

 

Exhibit 4.4

HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

NOVEMBER 10, 2005

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page
	1.	 	Registration Rights	 	 	1	 
	 
	 	1.1	 	Definitions	 	 	1	 
	 
	 	1.2	 	Request for Registration	 	 	2	 
	 
	 	1.3	 	Company Registration	 	 	4	 
	 
	 	1.4	 	Form S-3 Registration	 	 	5	 
	 
	 	1.5	 	Obligations of the Company	 	 	6	 
	 
	 	1.6	 	Information from Holder	 	 	7	 
	 
	 	1.7	 	Expenses of Registration	 	 	7	 
	 
	 	1.8	 	Delay of Registration	 	 	8	 
	 
	 	1.9	 	Indemnification	 	 	8	 
	 
	 	1.10	 	Reports Under the 1934 Act	 	 	10	 
	 
	 	1.11	 	Assignment of Registration Rights	 	 	10	 
	 
	 	1.12	 	Limitations on Subsequent Registration Rights	 	 	10	 
	 
	 	1.13	 	“Market Stand-Off” Agreement	 	 	11	 
	 
	 	1.14	 	Termination of Registration Rights	 	 	11	 
	2.	 	Covenants of the Company	 	 	12	 
	 
	 	2.1	 	Delivery of Financial Statements	 	 	12	 
	 
	 	2.2	 	Inspection	 	 	12	 
	 
	 	2.3	 	Termination of Information and Inspection Covenants	 	 	12	 
	 
	 	2.4	 	Right of First Offer	 	 	13	 
	 
	 	2.5	 	Proprietary Information and Inventions Agreements	 	 	14	 
	 
	 	2.6	 	Director Expenses	 	 	14	 
	 
	 	2.7	 	Issuance of Series C Preferred Stock	 	 	14	 
	3.	 	Miscellaneous	 	 	14	 
	 
	 	3.1	 	Successors and Assigns	 	 	14	 
	 
	 	3.2	 	Governing Law	 	 	15	 
	 
	 	3.3	 	Counterparts	 	 	15	 
	 
	 	3.4	 	Titles and Subtitles	 	 	15	 
	 
	 	3.5	 	Notices	 	 	15	 

i.

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Page
	 
	 	3.6	 	Expenses	 	 	15	 
	 
	 	3.7	 	Entire Agreement; Amendments and Waivers	 	 	15	 
	 
	 	3.8	 	Severability	 	 	15	 
	 
	 	3.9	 	Aggregation of Stock	 	 	15	 
	 
	 	3.10	 	Amendment of Prior Agreement	 	 	15	 

ii.

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

     THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 10th
day of November, 2005, by and among Hansen Medical, Inc., a Delaware corporation (the “Company”),
and the investors listed on Schedule A hereto, each of which is herein referred to as an
“Investor.”

RECITALS

     Whereas, certain of the Investors are purchasing shares of the Company’s Series C
Preferred Stock (the “Series C Preferred Stock”), pursuant to that certain Series C Preferred Stock
Purchase Agreement (the “Series C Agreement”) of even date herewith (the “Financing”);

     Whereas, the obligations in the Series C Agreement are conditioned upon the execution
and delivery of this Agreement;

     Whereas, certain of the Investors (the “Prior Investors”) are holders of the
Company’s Series A Preferred Stock (the “Series A Preferred Stock”) and Series B Preferred Stock
(the “Series B Preferred Stock,” and together with the Series A Preferred Stock and the Series C
Preferred Stock, the “Preferred Stock”);

     Whereas, the Prior Investors and the Company are parties to an Amended and Restated
Investors’ Rights Agreement dated May 21, 2004, as amended (the “Prior Agreement”);

     Whereas, the parties to the Prior Agreement desire to amend and restate the Prior
Agreement and accept the rights and covenants hereof in lieu of their rights and covenants under
the Prior Agreement; and

     WHEREAS, in order to induce the Investors to purchase the Series C Preferred Stock and invest
funds in the Company pursuant to the Series C Agreement, the Investors and the Company hereby agree
that this Agreement shall govern the rights of the Investors to cause the Company to register
shares of Common Stock issued or issuable to them and certain other matters as set forth herein;

          NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

          1. Registration Rights. The Company covenants and agrees as follows:

               1.1 Definitions. For purposes of this Section 1:

                    (a) The term “Act” means the Securities Act of 1933, as amended.

                    (b) The term “Form S-3” means such form under the Act as in effect on the date hereof or any
registration form under the Act subsequently adopted by the SEC that permits inclusion or
incorporation of substantial information by reference to other documents filed by the Company with
the SEC.

                    (c) “The term “Holder” means any person owning or having the right to acquire Registrable
Securities or any assignee thereof in accordance with Section 1.12 hereof, provided, however, that
Silicon Valley Bank and Gold Hill Venture Lending (collectively, the “Lenders”) and any transferees
of the Lenders shall be deemed “Holders” solely for the purposes of Sections 1.1, 1.3,

 

 

1.6, 1.7, 1.8, 1.9, 1.10, 1.13, 1.14 and 3 hereto and, provided further, that Intuitive
Surgical, Inc. shall be deemed to be a “Holder” solely for the purposes of Sections 1 and 3
hereto.”

                    (d) The term “Initial Offering” means the Company’s first firm commitment underwritten public
offering of its Common Stock under the Act. The term “Qualified Initial Offering” means an Initial
Offering in connection with which all outstanding shares of Preferred Stock shall automatically be
converted into shares of Common Stock pursuant to Article IV (D)(4)(l)(i)(B) of the Company’s
Amended and Restated Certificate of Incorporation, as may be amended from time to time.

                    (e) The term “1934 Act” means the Securities Exchange Act of 1934, as amended.

                    (f) The terms “register,” “registered,” and “registration” refer to a registration effected by
preparing and filing a registration statement or similar document in compliance with the Act, and
the declaration or ordering of effectiveness of such registration statement or document.

                    (g) The term “Registrable Securities” means (i) the Common Stock issuable or issued upon
conversion of the Preferred Stock, (ii) with respect to Section 2.4 only, the shares of Common
Stock issued to Frederic H. Moll, M.D., and (iii) any Common Stock of the Company issued as (or
issuable upon the conversion or exercise of any warrant, right or other security that is issued as)
a dividend or other distribution with respect to, or in exchange for, or in replacement of, the
shares referenced in (i) and (ii) above, excluding in all cases, however, any Registrable
Securities sold by a person in a transaction in which his rights under this Section 1 are not
assigned.

                    (h) The number of shares of “Registrable Securities” outstanding shall be determined by the
number of shares of Common Stock outstanding that are, and the number of shares of Common Stock
issuable pursuant to then exercisable or convertible securities that are, Registrable Securities.

                    (i) The term “Rule 144” shall mean Rule 144 under the Act.

                    (j) The term “Rule 144(k)” shall mean subsection (k) of Rule 144 under the Act.

                    (k) The term “SEC” shall mean the Securities and Exchange Commission.

               1.2 Request for Registration.

                    (a) Subject to the conditions of this Section 1.2, if the Company shall receive at any time
after the earlier of (i) November 10, 2008 or (ii) 180 days after the effective date of the Initial
Offering, a written request from the Holders of forty percent (40%) or more of the Registrable
Securities then outstanding (for purposes of this Section 1.2, the “Initiating Holders”) that the
Company file a registration statement under the Act covering the registration of Registrable
Securities with an anticipated aggregate offering price of at least $10,000,000, then the Company
shall, within twenty (20) days of the receipt thereof, give written notice of such request to all
Holders, and subject to the limitations of this Section 1.2, use all commercially reasonable
efforts to effect, as soon as practicable, the registration under the Act of all Registrable
Securities that the Holders request to be registered in a written request received by the Company
within twenty (20) days of the mailing of the Company’s notice pursuant to this Section 1.2(a).

2.

 

                    (b) If the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request
made pursuant to this Section 1.2 and the Company shall include such information in the written
notice referred to in Section 1.2(a). In such event the right of any Holder to include its
Registrable Securities in such registration shall be conditioned upon such Holder’s participation
in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting
(unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such
Holder) to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall enter into an underwriting agreement in customary form with the
underwriter or underwriters selected for such underwriting by the Company (which underwriter or
underwriters shall be reasonably acceptable to a majority in interest of the Initiating Holders).
Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Company
that marketing factors require a limitation on the number of securities underwritten (including
Registrable Securities), then the Company shall so advise all Holders of Registrable Securities
that would otherwise be underwritten pursuant hereto, and the number of shares that may be included
in the underwriting shall be allocated to the Holders of such Registrable Securities pro rata based
on the number of Registrable Securities held by all such Holders (including the Initiating
Holders). In no event shall any Registrable Securities be excluded from such underwriting unless
all other securities are first excluded. Any Registrable Securities excluded or withdrawn from
such underwriting shall be withdrawn from the registration.

                    (c) Notwithstanding the foregoing, the Company shall not be required to effect a registration
pursuant to this Section 1.2:

                         (i) in any particular jurisdiction in which the Company would be required to execute a general
consent to service of process in effecting such registration, unless the Company is already subject
to service in such jurisdiction and except as may be required under the Act; or

                         (ii) after the Company has effected two (2) registrations pursuant to this Section 1.2, and
such registrations have been declared or ordered effective; or

                         (iii) during the period starting with the date sixty (60) days prior to the Company’s good
faith estimate of the date of the filing of and ending on a date one hundred eighty (180) days
following the effective date of a Company-initiated registration subject to Section 1.3 below,
provided that the Company is actively employing in good faith all commercially reasonable efforts
to cause such registration statement to become effective; or

                         (iv) if the Initiating Holders propose to dispose of Registrable Securities that may be
registered on Form S-3 pursuant to Section 1.4 hereof; or

                         (v) if the Company shall furnish to Holders requesting a registration statement pursuant to
this Section 1.2 a certificate signed by the Company’s Chief Executive Officer or Chairman of the
Board stating that in the good faith judgment of the Board of Directors of the Company (the
“Board”), it would be seriously detrimental to the Company and its stockholders for such
registration statement to be effected at such time, in which event the Company shall have the right
to defer such filing for a period of not more than one hundred twenty (120) days after receipt of
the request of the Initiating Holders, provided that such right shall be exercised by the Company
not more than once in any twelve (12)-month period and provided further that the Company shall not
register any securities for the account of itself or any other stockholder during such one hundred
twenty (120) day period (other than a registration relating solely to the sale of securities of
participants in a Company stock plan).

3.

 

               1.3 Company Registration.

                    (a) If (but without any obligation to do so) the Company proposes to register (including for
this purpose a registration effected by the Company for stockholders other than the Holders) any of
its stock or other securities under the Act in connection with the public offering of such
securities (other than a registration relating solely to the sale of securities of participants in
a Company stock plan, a registration relating to a corporate reorganization or transaction under
Rule 145 of the Act, a registration on any form that does not include substantially the same
information as would be required to be included in a registration statement covering the sale of
the Registrable Securities, or a registration in which the only Common Stock being registered is
Common Stock issuable upon conversion of debt securities that are also being registered), the
Company shall, at such time, promptly give each Holder written notice of such registration. Upon
the written request of each Holder given within twenty (20) days after mailing of such notice by
the Company in accordance with Section 3.5, the Company shall, subject to the provisions of Section
1.3(c), use all commercially reasonable efforts to cause to be registered under the Act all of the
Registrable Securities that each such Holder requests to be registered.

                    (b) Right to Terminate Registration. The Company shall have the right to terminate or
withdraw any registration initiated by it under this Section 1.3 prior to the effectiveness of such
registration whether or not any Holder has elected to include securities in such registration. The
expenses of such withdrawn registration shall be borne by the Company in accordance with Section
1.7 hereof.

                    (c) Underwriting Requirements. In connection with any offering involving an
underwriting of shares of the Company’s capital stock, the Company shall not be required under this
Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the
terms of the underwriting as agreed upon between the Company and the underwriters selected by the
Company (or by other persons entitled to select the underwriters) and enter into an underwriting
agreement in customary form with such underwriters, and then only in such quantity as the
underwriters determine in their sole discretion will not jeopardize the success of the offering by
the Company. If the total amount of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the amount of securities sold other than by
the Company that the underwriters determine in their sole discretion is compatible with the success
of the offering, then the Company shall be required to include in the offering only that number of
such securities, including Registrable Securities, that the underwriters determine in their sole
discretion will not jeopardize the success of the offering. In no event shall any Registrable
Securities be excluded from such offering unless all other stockholders’ securities have been first
excluded. In the event that the underwriters determine that less than all of the Registrable
Securities requested to be registered can be included in such offering, then the Registrable
Securities that are included in such offering shall be apportioned pro rata among the selling
Holders based on the number of Registrable Securities held by all selling Holders or in such other
proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the
foregoing, in no event shall the amount of securities of the selling Holders included in the
offering be reduced below twenty-five percent (25%) of the total amount of securities included in
such offering, unless such offering is the initial public offering of the Company’s securities, in
which case the selling Holders may be excluded entirely if the underwriters make the determination
described above and no other stockholder’s securities are included in such offering. For purposes
of the preceding sentence concerning apportionment, for any selling stockholder that is a Holder of
Registrable Securities and that is a venture capital fund, partnership or corporation, the
affiliated venture capital funds, partners, retired partners and stockholders of such Holder, or
the estates and family members of any such partners and retired partners and any trusts for the
benefit of any of the foregoing persons shall be deemed to be a single “selling Holder,” and any
pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate amount
of Registrable Securities owned by all such related entities and individuals.

4.

 

               1.4 Form S-3 Registration. In case the Company shall receive from any Holder or
Holders of Registrable Securities (for purposes of this Section 1.4, the “Initiating Holders”) a
written request or requests that the Company effect a registration on Form S-3 and any related
qualification or compliance with respect to all or a part of the Registrable Securities owned by
such Holder or Holders, the Company shall:

                    (a) promptly give written notice of the proposed registration, and any related qualification
or compliance, to all other Holders; and

                    (b) use all commercially reasonable efforts to effect, as soon as practicable, such
registration and all such qualifications and compliances as may be so requested and as would permit
or facilitate the sale and distribution of all or such portion of such Holders’ Registrable
Securities as are specified in such request, together with all or such portion of the Registrable
Securities of any other Holders joining in such request as are specified in a written request given
within fifteen (15) days after receipt of such written notice from the Company, provided, however,
that the Company shall not be obligated to effect any such registration, qualification or
compliance, pursuant to this section 1.4:

                         (i) if Form S-3 is not available for such offering by the Holders;

                         (ii) if the Holders, together with the holders of any other securities of the Company entitled
to inclusion in such registration, propose to sell Registrable Securities and such other securities
(if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of
less than $2,000,000;

                         (iii) if within thirty (30) days of receipt of a written request from any Holder or Holders
pursuant to this Section 1.4, the Company gives notice to such Holder or Holders of the Company’s
intention to make a public offering within ninety (90) days, provided that such Holders were
permitted to register such shares as requested to be registered pursuant to Section 1.3 hereof
without reduction by the underwriter thereof;

                         (iv) if the Company shall furnish to Holders requesting a registration statement pursuant to
this Section 1.4 a certificate signed by the Company’s Chief Executive Officer or Chairman of the
Board stating that in the good faith judgment of the Board, it would be seriously detrimental to
the Company and its stockholders for such registration statement to be effected at such time, in
which event the Company shall have the right to defer such filing for a period of not more than one
hundred twenty (120) days after receipt of the request of the Initiating Holders, provided that
such right shall be exercised by the Company not more than once in any twelve (12)-month period and
provided further that the Company shall not register any securities for the account of itself or
any other stockholder during such one hundred twenty (120) day period (other than a registration
relating solely to the sale of securities of participants in a Company stock plan);

                         (v) if the Company has, within the twelve (12) month period preceding the date of such
request, already effected two (2) registrations on Form S-3 for the Holders pursuant to this
Section 1.4; or

                         (vi) in any particular jurisdiction in which the Company would be required to qualify to do
business or to execute a general consent to service of process in effecting such registration,
qualification or compliance.

5.

 

                    (c) If the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request
made pursuant to this Section 1.4 and the Company shall include such information in the written
notice referred to in Section 1.4(a). The provisions of Section 1.2(b) shall be applicable to such
request (with the substitution of Section 1.4 for references to Section 1.2).

                    (d) Subject to the foregoing, the Company shall file a registration statement covering the
Registrable Securities and other securities so requested to be registered as soon as practicable
after receipt of the request or requests of the Initiating Holders. Registrations effected
pursuant to this Section 1.4 shall not be counted as requests for registration effected pursuant to
Section 1.2.

               1.5 Obligations of the Company. Whenever required under this Section 1 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably
possible:

                    (a) prepare and file with the SEC a registration statement with respect to such Registrable
Securities and use all commercially reasonable efforts to cause such registration statement to
become effective, and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the Registration Statement
has been completed;

                    (b) prepare and file with the SEC such amendments and supplements to such registration
statement and the prospectus used in connection with such registration statement as may be
necessary to comply with the provisions of the Act with respect to the disposition of all
securities covered by such registration statement;

                    (c) furnish to the Holders such number of copies of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Act, and such other documents as they may
reasonably request in order to facilitate the disposition of Registrable Securities owned by them;

                    (d) use all commercially reasonable efforts to register and qualify the securities covered by
such registration statement under such other securities or Blue Sky laws of such jurisdictions as
shall be reasonably requested by the Holders, provided that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions;

                    (e) in the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement, in usual and customary form, with the managing underwriter of such
offering;

                    (f) notify each Holder of Registrable Securities covered by such registration statement at any
time when a prospectus relating thereto is required to be delivered under the Act of the happening
of any event as a result of which the prospectus included in such registration statement, as then
in effect, includes an untrue statement of a material fact or omits to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in the
light of the circumstances then existing;

6.

 

                    (g) cause all such Registrable Securities registered pursuant to this Section 1 to be listed
on a national exchange or trading system and on each securities exchange and trading system on
which similar securities issued by the Company are then listed; and

                    (h) provide a transfer agent and registrar for all Registrable Securities registered pursuant
hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the
effective date of such registration.

     Notwithstanding the provisions of this Section 1, the Company shall be entitled to suspend for
a reasonable period no longer than thirty (30) days (provided that such right shall be exercised by
the Company not more than twice in any twelve (12)-month period) the use of, or trading under, any
registration statement if the Company shall determine that any such filing or the sale of any
securities pursuant to such registration statement would in the good faith judgment of the Board:

                         (i) materially impede, delay or interfere with any material pending or proposed financing,
acquisition, corporate reorganization or other similar transaction involving the Company for which
the Board has authorized negotiations; or

                         (ii) require disclosure of material nonpublic information that, if disclosed at such time,
would be materially harmful to the interests of the Company and its stockholders; provided,
however, that during any such period all executive officers and directors of the Company are also
prohibited from selling securities of the Company (or any security of any of the Company’s
subsidiaries or affiliates).

     In the event of the suspension of effectiveness of any registration statement pursuant to this
Section 1.5, the applicable time period during which such registration statement is to remain
effective shall be extended by that number of days equal to the number of days the effectiveness of
such registration statement was suspended.

               1.6 Information from Holder. It shall be a condition precedent to the obligations of
the Company to take any action pursuant to this Section 1 with respect to the Registrable
Securities of any selling Holder that such Holder shall furnish to the Company such information
regarding itself, the Registrable Securities held by it, and the intended method of disposition of
such securities as shall be reasonably required to effect the registration of such Holder’s
Registrable Securities.

               1.7 Expenses of Registration. All expenses other than underwriting discounts and
commissions incurred in connection with registrations, filings or qualifications pursuant to
Sections 1.2, 1.3 and 1.4, including (without limitation) all registration, filing and
qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the
Company and the reasonable fees and disbursements of one counsel for the selling Holders (not to
exceed $35,000) shall be borne by the Company. Notwithstanding the foregoing, the Company shall
not be required to pay for any expenses of any registration proceeding begun pursuant to Section
1.2 or Section 1.4 if the registration request is subsequently withdrawn at the request of the
Holders of a majority of the Registrable Securities to be registered (in which case all
participating Holders shall bear such expenses pro rata based upon the number of Registrable
Securities that were to be included in the withdrawn registration), unless, in the case of a
registration requested under Section 1.2, the Holders of a majority of the Registrable Securities
agree to forfeit their right to one demand registration pursuant to Section 1.2 and provided,
however, that if at the time of such withdrawal, the Holders have learned of a material adverse
change in the condition, business or prospects of the Company from that known to the Holders at the
time of their request and have withdrawn the request with reasonable promptness following
disclosure by the Company of such

7.

 

material adverse change, then the Holders shall not be required to pay any of such expenses
and shall retain their rights pursuant to Section 1.2 and 1.4.

               1.8 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the result of any controversy
that might arise with respect to the interpretation or implementation of this Section 1.

               1.9 Indemnification. In the event any Registrable Securities are included in a
registration statement under this Section 1:

                    (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder,
the partners, members, officers, directors and stockholders of each Holder, legal counsel and
accountants for each Holder, any underwriter (as defined in the Act) for such Holder and each
person, if any, who controls such Holder or underwriter within the meaning of the Act or the 1934
Act, against any losses, claims, damages or liabilities (joint or several) to which they may become
subject under the Act, the 1934 Act, any state securities laws or any rule or regulation
promulgated under the Act, insofar as such losses, claims, damages, or liabilities (or actions in
respect thereof) arise out of or are based upon any of the following statements, omissions or
violations (collectively a “Violation”): (i) any untrue statement or alleged untrue statement of a
material fact contained in such registration statement, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or
alleged omission to state in such registration statement a material fact required to be stated
therein, or necessary to make the statements therein not misleading or (iii) any violation or
alleged violation by the Company of the Act, the 1934 Act, any state securities laws or any rule or
regulation promulgated under the Act, the 1934 Act or any state securities laws, and the Company
will reimburse each such Holder, underwriter, controlling person or other aforementioned person for
any legal or other expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, liability or action as such expenses are incurred;
provided, however, that the indemnity agreement contained in this subsection l.9(a) shall not apply
to amounts paid in settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Company (which consent shall not be unreasonably
withheld), nor shall the Company be liable in any such case for any such loss, claim, damage,
liability or action to the extent that it arises out of or is based upon a Violation that occurs in
reliance upon and in conformity with written information furnished expressly for use in connection
with such registration by any such Holder, underwriter, controlling person or other aforementioned
person; provided further, however, that the foregoing indemnity agreement with respect to any
preliminary prospectus shall not inure to the benefit of any Holder or underwriter or other
aforementioned person, or any person controlling such Holder or underwriter, from whom the person
asserting any such losses, claims, damages or liabilities purchased shares in the offering, if a
copy of the most current prospectus was not sent or given by or on behalf of such Holder or
underwriter or other aforementioned person to such person, if required by law to have been so
delivered, at or prior to the written confirmation of the sale of the shares to such person, and if
the prospectus (as so amended or supplemented) would have cured the defect giving rise to such
loss, claim, damage or liability.

                    (b) To the extent permitted by law, each selling Holder will indemnify and hold harmless the
Company, each of its directors, each of its officers who has signed the registration statement,
each person, if any, who controls the Company within the meaning of the Act, legal counsel and
accountants for the Company, any underwriter, any other Holder selling securities in such
registration statement and any controlling person of any such underwriter or other Holder, against
any losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons
may become subject, under the Act, the 1934 Act, any state securities laws or any rule or
regulation promulgated under the Act, the 1934 Act or any state securities laws, insofar as such
losses, claims,

8.

 

damages or liabilities (or actions in respect thereto) arise out of or are based upon any
Violation, in each case to the extent (and only to the extent) that such Violation occurs in
reliance upon and in conformity with written information furnished by such Holder expressly for use
in connection with such registration; and each such Holder will reimburse any person intended to be
indemnified pursuant to this subsection l.9(b) for any legal or other expenses reasonably incurred
by such person in connection with investigating or defending any such loss, claim, damage,
liability or action as such expenses are incurred; provided, however, that the indemnity agreement
contained in this subsection l.9(b) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability or action if such settlement is effected without the consent of the Holder
(which consent shall not be unreasonably withheld), and provided that in no event shall any
indemnity under this subsection l.9(b) exceed the net proceeds from the offering received by such
Holder.

                    (c) Promptly after receipt by an indemnified party under this Section 1.9 of notice of the
commencement of any action (including any governmental action), such indemnified party will, if a
claim in respect thereof is to be made against any indemnifying party under this Section 1.9,
deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying
party shall have the right to participate in and, to the extent the indemnifying party so desires,
jointly with any other indemnifying party similarly noticed, to assume the defense thereof with
counsel mutually satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties that may be represented without conflict by one
counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid
by the indemnifying party, if representation of such indemnified party by the counsel retained by
the indemnifying party would be inappropriate due to actual or potential differing interests
between such indemnified party and any other party represented by such counsel in such proceeding.
The failure to deliver written notice to the indemnifying party within a reasonable time of the
commencement of any such action, if prejudicial to its ability to defend such action, shall relieve
such indemnifying party of any liability to the indemnified party under this Section 1.9, but the
omission to so deliver written notice to the indemnifying party will not relieve it of any
liability that it may have to any indemnified party otherwise than under this Section 1.9.

                    (d) If the indemnification provided for in this Section 1.9 is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim,
damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying such
indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified
party as a result of such loss, liability, claim, damage or expense in such proportion as is
appropriate to reflect the relative fault of the indemnifying party on the one hand and the
indemnified party on the other hand in connection with the statements or omissions that resulted in
such loss, liability, claim, damage or expense, as well as any other relevant equitable
considerations; provided, however, that no contribution by any Holder, when combined with any
amounts paid by such Holder pursuant to Section 1.9(b), shall exceed the net proceeds from the
offering received by such Holder. The relative fault of the indemnifying party and the indemnified
party shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a material fact relates
to information supplied by the indemnifying party or by the indemnified party and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission.

                    (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the
underwritten public offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control.

9.

 

                    (f) The obligations of the Company and Holders under this Section 1.9 shall survive the
completion of any offering of Registrable Securities in a registration statement under this Section
1 and otherwise.

               1.10 Reports Under the 1934 Act. With a view to making available to the Holders the
benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a
Holder to sell securities of the Company to the public without registration or pursuant to a
registration on Form S-3, the Company agrees to:

                    (a) make and keep public information available, as those terms are understood and defined in
Rule 144, at all times after the effective date of the Initial Offering;

                    (b) file with the SEC in a timely manner all reports and other documents required of the
Company under the Act and the 1934 Act; and

                    (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith
upon request (i) a written statement by the Company that it has complied with the reporting
requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first
registration statement filed by the Company), the Act and the 1934 Act (at any time after it has
become subject to such reporting requirements), or that it qualifies as a registrant whose
securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of
the most recent annual or quarterly report of the Company and such other reports and documents so
filed by the Company, and (iii) such other information as may be reasonably requested to avail any
Holder of any rule or regulation of the SEC that permits the selling of any such securities without
registration or pursuant to such form.

               1.11 Assignment of Registration Rights. The rights to cause the Company to register
Registrable Securities pursuant to this Section 1 may be assigned (but only with all related
obligations) by a Holder to a transferee or assignee of such securities that (i) is a subsidiary,
affiliate, parent, partner, member, limited partner, retired partner, retired member or stockholder
of a Holder, (ii) is a Holder’s family member or trust for the benefit of an individual Holder, or
(iii) acquires at least twenty percent (20%) of a Holder’s shares of Registrable Securities
(subject to appropriate adjustment for stock splits, stock dividends, combinations or the like),
provided: (a) the Company is, within a reasonable time after such transfer, furnished with written
notice of the name and address of such transferee or assignee and the securities with respect to
which such registration rights are being assigned; (b) such transferee or assignee agrees in
writing to be bound by and subject to the terms and conditions of this Agreement, including,
without limitation, the provisions of Section 1.13 below; and (c) such assignment shall be
effective only if immediately following such transfer the further disposition of such securities by
the transferee or assignee is restricted under the Act.

               1.12 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of sixty percent
(60%) of the Registrable Securities, enter into any agreement with any holder or prospective holder
of any securities of the Company that would allow such holder or prospective holder (a) to include
any of such securities in any registration filed under Section 1.2, Section 1.3 or Section 1.4
hereof, unless under the terms of such agreement, such holder or prospective holder may include
such securities in any such registration only to the extent that the inclusion of such securities
will not reduce the amount of the Registrable Securities of the Holders that are included or (b) to
demand registration of their securities.

10.

 

               1.13 “Market Stand-Off” Agreement.

                    (a) Each Holder hereby agrees that it will not, without the prior written consent of the
managing underwriter, during the period commencing on the date of the final prospectus relating to
the Company’s Initial Offering and ending on the date specified by the Company and the managing
underwriter (such period not to exceed one hundred eighty (l80) days) (i) lend, offer, pledge,
sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly
or indirectly, any shares of Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock held immediately prior to the effectiveness of the Registration
Statement for such offering, or (ii) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of the Common Stock,
whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of
Common Stock or other securities, in cash or otherwise. The foregoing provisions of this Section
1.13 shall apply only to the Company’s initial offering of equity securities, shall not apply to
the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be
applicable to the Holders if all officers, directors, and greater than five percent (5%)
stockholders of the Company enter into similar agreements. The underwriters in connection with the
Company’s Initial Offering are intended third-party beneficiaries of this Section 1.13 and shall
have the right, power and authority to enforce the provisions hereof as though they were a party
hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by
the underwriters in the Company’s Initial Offering that are consistent with this Section 1.13 or
that are necessary to give further effect thereto. Any discretionary waiver or termination of the
restrictions on any or all of such agreements by the Company or the underwriters shall apply to all
Holders subject to such agreements pro rata based on the number of shares subject to such
agreement.

          In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions
with respect to the Registrable Securities of each Holder (and the shares or securities of every
other person subject to the foregoing restriction) until the end of such period.

                    (b) Each Holder agrees that a legend reading substantially as follows shall be placed on all
certificates representing all Registrable Securities of each Holder (and the shares or securities
of every other person subject to the restriction contained in this Section 1.13):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP
TO 180 DAYS AFTER THE EFFECTIVE DATE OF THE ISSUER’S REGISTRATION STATEMENT FILED
UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE
ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER’S
PRINCIPAL OFFICE. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES.”

               1.14 Termination of Registration Rights. No Holder shall be entitled to exercise any
right provided for in this Section 1 (i) after five (5) years following the consummation of the
Initial Offering, or (ii) as to any Holder, such earlier time after the Initial Offering at which
such Holder (A) can sell all shares held by it in compliance with Rule 144(k) or (B) holds one
percent (1%) or less of the Company’s outstanding Common Stock and all Registrable Securities held
by such Holder (together with any affiliate of the Holder with whom such Holder must aggregate its
sales under Rule 144) can be sold in any three (3)-month period without registration in compliance
with Rule 144.

11.

 

          2. Covenants of the Company.

               2.1 Delivery of Financial Statements. The Company shall, upon request, deliver to
each Investor (or transferee of an Investor) that holds at least 500,000 shares of Registrable
Securities, calculated in accordance with Section 3.9 below (subject to appropriate adjustment for
stock splits, stock dividends, combinations or the like) (a “Major Investor”):

                    (a) as soon as practicable, but in any event within one hundred eighty (180) days after the
end of each fiscal year of the Company, an income statement for such fiscal year, a balance sheet
of the Company and statement of stockholders’ equity as of the end of such year, and a statement of
cash flows for such year, such year-end financial reports to be in reasonable detail, prepared in
accordance with generally accepted accounting principles (“GAAP”), and audited and certified by
independent public accountants of nationally recognized standing selected by the Company;

                    (b) within thirty (30) days of the end of each quarter, an unaudited income statement and
statement of cash flows and balance sheet for and as of the end of such month, in reasonable
detail;

                    (c) upon request of a Major Investor, as soon as practicable after the end of each month, and
in any event within thirty (30) days thereafter, a balance sheet of the Company as of the end of
each such month, and a statement of income and a statement of cash flows of the Company for such
month and for the current fiscal year to date, including a comparison to plan figures for such
period, prepared in accordance with generally accepted accounting principles consistently applied
(except as noted thereon), with the exception that no notes need be attached to such statements and
month-end audit adjustments may not have been made.

                    (d) upon request of a Major Investor, a budget and business plan for the next fiscal year, a
budget and business plan for the next fiscal year, prepared on a monthly basis, and, as soon as
prepared, any other budgets or revised budgets prepared by the Company;

                    (e) upon request of a Major Investor, an annual summary capitalization table of the Company;
and

                    (f) such other information relating to the financial condition, business or corporate affairs
of the Company as the Major Investor may from time to time request, provided, however, that the
Company shall not be obligated under this subsection (f) or any other subsection of Section 2.1 to
provide information that it deems in good faith to be a trade secret or similar confidential
information.

               2.2 Inspection. The Company shall permit each Major Investor, at such Major
Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account
and records and to discuss the Company’s affairs, finances and accounts with its officers, all at
such reasonable times as may be requested by the Major Investor; provided, however, that the
Company shall not be obligated pursuant to this Section 2.2 to provide access to any information
that it reasonably considers to be a trade secret or similar confidential information.

               2.3 Termination of Information and Inspection Covenants. The covenants set forth in
Sections 2.1 and 2.2 shall terminate and be of no further force or effect upon the earlier to occur
of (i) a Qualified Initial Offering, (ii) when the Company first becomes subject to the periodic
reporting requirements of Sections 12(g) or 15(d) of the 1934 Act, whichever event shall first
occur or

12.

 

(iii) the consummation of an Asset Transfer or Acquisition, as such terms are defined in the
Company’s Amended and Restated Certificate of Incorporation (as amended from time to time).

               2.4 Right of First Offer. Subject to the terms and conditions specified in this
Section 2.4, the Company hereby grants to each Major Investor a right of first offer with respect
to future sales by the Company of its Shares (as hereinafter defined). For purposes of this
Section 2.4, the term Major Investor includes any general partners and affiliates of a Major
Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted
it among itself and its partners and affiliates in such proportions as it deems appropriate. In
addition, for purposes of this Section 2.4 only, the term “Major Investor” includes Frederic H.
Moll, M.D.

          Each time the Company proposes to offer any shares of, or securities convertible into or
exchangeable or exercisable for any shares of, its capital stock (“Shares”), the Company shall
first make an offering of such Shares to each Major Investor in accordance with the following
provisions:

                    (a) The Company shall deliver a notice in accordance with Section 3.5 (“Notice”) to the Major
Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares
to be offered and (iii) the price and terms upon which it proposes to offer such Shares.

                    (b) By written notification received by the Company within twenty (20) calendar days after the
giving of Notice, each Major Investor may elect to purchase, at the price and on the terms
specified in the Notice, up to that portion of such Shares that equals the proportion that the
number of shares of Common Stock that are Registrable Securities issued and held by such Major
Investor (assuming full conversion and exercise of all convertible and exercisable securities then
outstanding) bears to the total number of shares of Common Stock of the Company then outstanding
(assuming full conversion and exercise of all convertible and exercisable securities then
outstanding). The Company shall promptly, in writing, inform each Major Investor that purchases
all the shares available to it (each, a “Fully-Exercising Investor”) of any other Major Investor’s
failure to do likewise. During the 10-day period commencing after receipt of such information,
each Fully-Exercising Investor shall be entitled to obtain that portion of the Shares for which
Major Investors were entitled to subscribe but which were not subscribed for by the Major Investors
that is equal to the proportion that the number of shares of Common Stock issued and held, or
issuable upon conversion and exercise of all convertible or exercisable securities then held, by
such Fully-Exercising Investor bears to the total number of shares of common Stock then outstanding
(assuming full conversion and exercise of all convertible or exercisable securities).

                    (c) If all Shares that Major Investors are entitled to obtain pursuant to subsection 2.4(b)
are not elected to be obtained as provided in subsection 2.4(b) hereof, the Company may, during the
forty five (45) day period following the expiration of the period provided in subsection 2.4(b)
hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price
not less than that, and upon terms no more favorable to the offeree than those, specified in the
Notice. If the Company does not enter into an agreement for the sale of the Shares within such
period, or if such agreement is not consummated within sixty (60) days of the execution thereof,
the right provided hereunder shall be deemed to be revived and such Shares shall not be offered
unless first reoffered to the Major Investors in accordance herewith.

                    (d) The right of first offer in this Section 2.4 shall not be applicable to (i) the issuance
or sale of shares of Common Stock (or options therefor) after the date hereof to employees,
officers or directors of, or consultants or advisors to the Company or any subsidiary pursuant to
stock purchase or stock option plans or other arrangements that are approved by the Board; (ii) the

13.

 

issuance of securities pursuant to a bona fide, firmly underwritten public offering of shares
of Common Stock registered under the Act, (iii) the issuance of securities pursuant to the
conversion or exercise of convertible or exercisable securities, (iv) the issuance of securities
pursuant to a merger, consolidation, acquisition, strategic alliance or similar business
combination approved by the Board, including a majority of the directors designated by the holders
of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively,
the “Preferred Directors”), (v) the issuance and sale of Series C Preferred Stock pursuant to the
Series C Agreement, (vi) the issuance of securities issued pursuant to any equipment loan or
leasing arrangement, real property leasing arrangement or debt financing from a bank or similar
financial institution approved by the Board, including a majority of the Preferred Directors, (vii)
the issuance of securities in connection with strategic transactions involving the Company and
other entities, including (A) joint ventures, manufacturing, marketing or distribution arrangements
or (B) technology transfer or development arrangements; provided that the issuance of shares
therein has been approved by the Board, including a majority of the Preferred Directors; provided
further, that the primary purpose of such strategic transaction may not be to raise capital in an
equity financing or (viii) the issuance of securities that, with unanimous approval of the Board,
are not offered to any existing stockholder of the Company. In addition to the foregoing, the
right of first offer in this Section 2.4 shall not be applicable with respect to any Major Investor
in any subsequent offering of Shares if (i) at the time of such offering, the Major Investor is not
an “accredited investor,” as that term is then defined in Rule 501(a) of the Act and (ii) such
offering of Shares is otherwise being offered only to accredited investors.

                    (e) The rights provided in this Section 2.4 may not be assigned or transferred separate from
the Shares by any Major Investor; provided, however, that a Major Investor that is a venture
capital fund may assign or transfer such rights to an affiliated venture capital fund.

                    (f) The covenants set forth in this Section 2.4 shall terminate and be of no further force or
effect upon the consummation of (i) the Company’s sale of its Common Stock or other securities
pursuant to Registration Statement under the Act (other than a registration statement relating
either to the sale of securities to employees of the Company pursuant to its stock option, stock
purchase or similar plan or a SEC Rule 145 transaction) or (ii) an Asset Transfer or Acquisition,
as such terms are defined in the Company’s Amended and Restated Certificate of Incorporation (as
amended from time to time).

               2.5 Proprietary Information and Inventions Agreements. The Company shall require all
employees and consultants to execute and deliver a Proprietary Information and Inventions Agreement
in substantially the form approved by the Board.

               2.6 Director Expenses. The Company shall pay the reasonable expenses incurred by
directors representing the Major Investors to attend meetings of the Board.

               2.7 Issuance of Series C Preferred Stock. The Company shall not issue shares of
Series C Preferred Stock after the date hereof without the consent of the Board, including the
consent of a majority of the Preferred Directors.

          3. Miscellaneous.

               3.1 Successors and Assigns. Except as otherwise provided herein, the terms and
conditions of this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties (including transferees of any shares of Registrable
Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party
other than the parties hereto or their respective successors and assigns any rights, remedies,
obligations or liabilities under or by reason of this Agreement, except as expressly provided in
this Agreement.

14.

 

               3.2 Governing Law. This Agreement shall be governed by and construed under the laws
of the State of California as applied to agreements among California residents entered into and to
be performed entirely within California.

               3.3 Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

               3.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement.

               3.5 Notices. All notices and other communications given or made pursuant hereto shall
be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be
notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business
hours of the recipient; if not, then on the next business day, (iii) five (5) days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one
(1) day after deposit with a nationally recognized overnight courier, specifying next day delivery,
with written verification of receipt. All communications shall be sent to the respective parties
at the addresses set forth on the signature pages attached hereto (or at such other addresses as
shall be specified by notice given in accordance with this Section 3.5).

               3.6 Expenses. If any action at law or in equity is necessary to enforce or interpret
the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees,
costs and necessary disbursements in addition to any other relief to which such party may be
entitled.

               3.7 Entire Agreement; Amendments and Waivers. This Agreement (including the Exhibits
hereto, if any) constitutes the full and entire understanding and agreement among the parties with
regard to the subjects hereof and thereof. Any term of this Agreement (other than Section 2.1,
Section 2.2, Section 2.3 and Section 2.4) may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or
prospectively) only with the written consent of the Company and the holders of sixty-six and
two-thirds percent (662/3%) of the Registrable Securities. The provisions of Section
2.1, Section 2.2, Section 2.3 and Section 2.4 may be amended or waived (either generally or in a
particular instance and either retroactively or prospectively) only with the written consent of the
Company and the holders of sixty-six and two-thirds percent (662/3%) of the Registrable
Securities that are held by Major Investors. Any amendment or waiver effected in accordance with
this paragraph shall be binding upon each holder of any Registrable Securities, each future holder
of all such Registrable Securities, and the Company.

               3.8 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provision(s) shall be excluded from this Agreement and the
balance of the Agreement shall be interpreted as if such provision(s) were so excluded and shall be
enforceable in accordance with its terms.

               3.9 Aggregation of Stock. All shares of Registrable Securities held or acquired by
affiliated entities (including affiliated venture capital funds) or persons shall be aggregated
together for the purpose of determining the availability of any rights under this Agreement.

               3.10 Amendment of Prior Agreement. The Prior Agreement is hereby amended and
superseded in its entirety and restated herein. Upon execution by the requisite parties, all
provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released
and superseded in their entirety and shall have no further force to effect.

15.

 

[Signature Pages Follow]

16.

 

          IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	HANSEN MEDICAL, INC.
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ James Feenstra
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	James Feenstra	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	President and Chief Operating Officer	 	 
	 
	 	 	 	 	 	 
	 

	 	Address:
	 	380 North Bernardo Avenue	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	Mountain View, CA 94043	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

          IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 
	 

	 	INVESTOR:	 	 
	 
	 	 	 	 
	 

	 	VANGUARD VII, L.P.	 	 
	 

	 	VANGUARD VII-A, L.P.	 	 
	 

	 	VANGUARD VII ACCREDITED AFFILIATES FUND, L.P.	 	 
	 

	 	VANGUARD VII QUALIFIED AFFILIATES FUND, L.P.	 	 
	 
	 	 	 	 
	 

	 	By its General Partner,	 	 
	 

	 	VANGUARD VII VENTURE PARTNERS, L.L.C.	 	 
	 
	 	 	 	 
	 

	 	/s/ Thomas C. McConnell
 

Thomas C. McConnell, Managing Member
	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

          IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTORS:	 	 
	 
	 	 	 	 	 	 
	 	 	THOMAS WEISEL HEALTHCARE VENTURE
PARTNERS, L.P.	 	 
	 
	 	 	 	 	 	 
	 	 	By: THOMAS WEISEL HEALTHCARE VENTURES
PARTNERS LLC	 	 
	 

	 	 	 	Its General Partner	 	 
	 
	 	 	 	 	 	 
	 	 	By: THOMAS WEISEL CAPITAL MANAGEMENT
LLC	 	 
	 

	 	 	 	Its Managing Member	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ James Shapiro
 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	James Shapiro	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	Partner	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTOR:
	 
	 	 	DE NOVO VENTURES II, L.P.
	 
	 

	 	By:
	 	De Novo Management II, L.L.C.,	 	 
	 

	 	 	 	its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ F.T. Jay Watkins
	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Name: F.T. Jay Watkins
	 
	 	 	 	 	 	 
	 	 	Title: Managing Director or Authorized Signatory

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 
	 	INVESTORS:

PROSPECT VENTURE PARTNERS II, L.P.

 	 
	 	By:  	/s/ Russell Hirsch
 	 
	 	 	Russell Hirsch 	 
	 	 	Managing Member of

Prospect Management Co. II, LLC

Its General Partner 	 
	 
	 	PROSPECT ASSOCIATES II, L.P.

 	 
	 	By:  	/s/ Russell Hirsch
 	 
	 	 	Russell Hirsch 	 
	 	 	Managing Member of

Prospect Management Co. II, LLC

Its General Partner 	 
	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 
	 

	 	INVESTORS:
	 	 
	 
	 	 	 	 
	 

	 	SKYLINE VENTURE PARTNERS III, L.P.	 	 
	 
	 	 	 	 
	 

	 	By: Skyline Venture Management III, LLC	 	 
	 
	 	 	 	 
	 

	 	Its: General Partner	 	 
	 
	 	 	 	 
	 

	 	/s/ John G. Freund	 	 
	 

	 	 	 	 
	 

	 	By: John G. Freund	 	 
	 

	 	Its: Managing Director	 	 
	 
	 	 	 	 
	 

	 	SKYLINE VENTURE PARTNERS	 	 
	 

	 	QUALIFIED PURCHASER FUND III, L.P.	 	 
	 
	 	 	 	 
	 

	 	By: Skyline Venture Management III, LLC	 	 
	 
	 	 	 	 
	 

	 	Its: General Partner	 	 
	 
	 	 	 	 
	 

	 	/s/ John G. Freund	 	 
	 

	 	 	 	 
	 

	 	By: John G. Freund	 	 
	 

	 	Its: Managing Director	 	 
	 
	 	 	 	 
	 

	 	SKYLINE EXPANSION FUND, L.P.	 	 
	 
	 	 	 	 
	 

	 	By: Skyline Expansion Fund Management, LLC	 	 
	 
	 	 	 	 
	 

	 	Its: General Partner	 	 
	 
	 	 	 	 
	 

	 	By: Skyline Venture Management III, LLC	 	 
	 
	 	 	 	 
	 

	 	Its: General Partner	 	 
	 
	 	 	 	 
	 

	 	/s/ John G. Freund	 	 
	 

	 	 	 	 
	 

	 	By: John G. Freund	 	 
	 

	 	  Its: Managing Director	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 
	 	INVESTOR:

FREDERIC H. MOLL, M.D.

 	 
	 	/s/ Frederic H. Moll
 	 
	 	 	 
	 	 	 
	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTORS:  
	 
	 	 	SAPIENT CAPITAL, L.P.
	 
	 	 	By: Sapient Capital Management, L.P.
	 	 	Its: General Partner
	 
	 	 	By: Sapient Capital Management, L.L.C.
	 	 	Its: General Partner
	 
	 

	 	By:
	 	/s/ Mitchell Dann	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Mitchell Dann,	 	 
	 

	 	 	 	Its: Principal	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTORS:  
	 
	 	 	 	 	 	 
	 	 	THE WILLIAM P. UNGER AND TERESA R. LUCHSINGER
FAMILY TRUST, DATED 12/19/90	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ William D. Unger	 	 
	 

	 	 	 	 	 	 
	 	 	Print Name: William D. Unger	 	 
	 	 	Its: TTE
	 
	 	 	 	 	 	 
	 	 	ROBERT HARDWIN AND TAMARA MEAD REVOCABLE LIVING
 TRUST, DATED DECEMBER 2, 2002	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Robert Hardwin-Mead	 	 
	 

	 	 	 	 	 	 
	 	 	Print Name: Robert Hardwin-Mead
	 	 	Its: Trustee
	 
	 	 	 	 	 	 
	 	 	YOCK FAMILY REVOCABLE TRUST, DATED 7/21/93	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Paul G. Yock	 	 
	 

	 	 	 	 	 	 
	 	 	Print Name: Paul G. Yock
	 	 	Its: Trustee
	 
	 	 	 	 	 	 
	 	 	HEWM/VLG INVESTMENT LLC
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Mark Royer	 	 
	 

	 	 	 	 	 	 
	 	 	Print Name: Mark Royer
	 	 	Its: Fund Manager
	 
	 	 	 	 	 	 
	 	 	DAVID S. BRADFORD REVOCABLE TRUST
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ David S. Bradford	 	 
	 

	 	 	 	 	 	 
	 	 	Print Name: David S. Bradford
	 

	 	Its:	 	Trustee 	 	 
	 

	 	 	 	 	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 	 	 
	 	 	INVESTORS:  
	 
	 	 	 	 	 	 	 	 
	 	 	GARVIE FAMILY TRUST I
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	Print Name:	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	Its:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	OMEAH LIMITED PARTNERSHIP
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	Print Name:	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	Its:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	G. L. CABOT HENDERSON
	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	JOHNSON & JOHNSON DEVELOPMENT CORPORATION
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	Print Name:	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	Its:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	ROBERT W. CUNNINGHAM, AS TRUSTEE OF THE ENDOVIA
MEDICAL INC. NOTEHOLDERS’ LIQUIDATING TRUST	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	Print Name:	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	Its:	 	 	 	 	 	 
	 	 	 	 	 	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 	 	 
	 	 	INVESTORS:	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	PROGRESS NOW! (OVERSEAS), LTD.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	Print Name:	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	Its:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	DON G. FISHER	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	GEORGE VUJNOVICH	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	SILICON VALLEY BANK	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	Print Name:	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	Its:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	GOLD HILL VENTURE LENDING, LLC	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	Print Name:	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	Its:	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	SEAFLOWER BIOVENTURE FUND II, LLC
	 	 	SEAFLOWER HEALTH & TECHNOLOGY FUND LLC	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	By:	 	/s/ Alexander Moot	 	 
	 	 	 	 	 	 	 
	 	 	Print Name:	 	Alexander Moot	 	 
	 	 	Their:	 	 Manager	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTOR:	 	 
	 
	 	 	 	 	 	 
	 	 	G&H PARTNERS	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Jonathan Gleason	 	 
	 

	 	 	 	 	 	 
	 
	 

	 	Name:
	 	Jonathan Gleason	 	 
	 
	 

	 	Its:	 	 	 	 
	 

	 	 	 	 	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTOR:
	 
	 	 	 	 	 	 
	 	 	GC&H INVESTMENTS, LLC  
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ John L. Cardoza	 	 
	 

	 	 	 	 	 	 
	 
	 

	 	Name:
	 	John L. Cardoza	 	 
	 
	 

	 	Its:
	 	Managing Member	 	 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTOR:  
	 
	 	 	 	 	 	 
	 	 	INTUITIVE SURGICAL, INC.
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Ben Gong	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Ben Gong	 	 
	 

	 	 	 	Chief Financial Officer	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTOR:  
	 
	 	 	 	 	 	 
	 	 	CHTP/BRS ASSOCIATES, LLC
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ David F. Hendren	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Print Name: David F. Hendren
	 	 	Print Title: Managing Director

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTOR:  
	 
	 	 	 	 	 	 
	 	 	PHIGHT, LLC
	 
	 

	 	By:
	 	/s/ Phillip H. Knight	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Print Name: Phillip H. Knight
	 	 	Print Title: Majority Partner

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTOR:
	 
	 	 	 	 	 	 
	 	 	GRANT AND JEANNETTE HEIDRICH, TRUSTEES OF THE
HEIDRICH COMMUNITY PROPERTY TRUST, UDT 10/84	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ A. Grant Heidrich III	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Print Name: A. Grant Heidrich III	 	 
	 
	 	 	Print Title: Trustee	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTOR:  
	 
	 	 	 	 	 	 
	 	 	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR
UNIVERSITY (DAPER I)	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Martina S. Poquet	 	 
	 

	 	 	 	 	 	 
	 	 	For Tyler Edelstein
	 

	 	 	 	Managing Director, Separate Investments	 	 

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

     IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	INVESTOR:  
	 
	 	 	 	 	 	 
	 	 	RAHN GROUP, LLC
	 
	 

	 	By:
	 	/s/ Noel P. Rahn	 	 
	 

	 	 	 	 	 	 
	 	 	Print Name: Noel P. Rahn
	 	 	Print Title: Partner In Charge

SIGNATURE PAGE TO HANSEN MEDICAL, INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

SCHEDULE A

	 	 	 
	Thomas Weisel Healthcare Venture Partners, L.P.

	 	 
	One Montgomery Street
	 	 
	San Francisco, CA 94104
	 	 
	 
	 	 
	De Novo Ventures
	 	 
	1550 El Camino Real, Suite 150
	 	 
	Menlo Park, CA 94025
	 	 
	 
	 	 
	Prospect Venture Partners II, L.P.
	 	 
	435 Tasso Street, Suite 200
	 	 
	Palo Alto, CA 94301
	 	 
	 
	 	 
	Prospect Associates II, L.P.
	 	 
	435 Tasso Street, Suite 200
	 	 
	Palo Alto, CA 94301
	 	 
	 
	 	 
	Skyline Venture Partners III, L.P.
	 	 
	125 University Avenue
	 	 
	Palo Alto, CA 94301
	 	 
	 
	 	 
	Skyline Venture Partners Qualified Purchaser Fund III, L.P.
	 	 
	125 University Avenue
	 	 
	Palo Alto, CA 94301
	 	 
	 
	 	 
	Skyline Expansion Fund, L.P.
	 	 
	125 University Avenue
	 	 
	Palo Alto, CA 94301
	 	 
	 
	 	 
	Sapient Capital
	 	 
	P.O. Box 1590
	 	 
	4020 West Lake Creek Dr.
	 	 
	Wilson, WY 83014
	 	 
	 
	 	 
	Frederic H. Moll, M.D.
	 	 
	c/o Hansen Medical
	 	 
	380 North Bernardo Avenue
	 	 
	Mountain View, CA 94043
	 	 
	 
	 	 
	CHTP/BRS Associates, LLC
	 	 
	c/o Catalyst Health & Technology Partners LLC
	 	 
	One Gateway Center, Suite 312
	 	 
	Newton, MA 02485
	 	 
	 
	 	 
	Omeah Limited Partnership
	 	 
	Attn: Robert Stuart Garvie III
	 	 
	774 Mays Boulevard
	 	 
	Incline Village, NV 89451
	 	 
	 
	 	 

	 	 	 
	Progress Now! (Overseas), Ltd.
	 	 
	Attn: Urs Altorfer
	 	 
	c/o Progress Now! invest AG
	 	 
	Bahnhofplatz 65 CH-8501
	 	 
	Frauenfeld, SWITZERLAND
	 	 
	 
	 	 
	The William D. Unger and Teresa R. Luchsinger Family Trust, dated 12/19/90
	 	 
	24 Robleda Drive
	 	 
	Atherton, CA 94027
	 	 
	 
	 	 
	Robert Hardwin Mead and Tamara Lynn Mead, or their successors, as Trustees of the Robert
Hardwin and Tamara Mead Revocable Living Trust, dated December 2, 2002
	 	 
	940 Roble Ridge Road
	 	 
	Palo Alto, CA 94306-2609
	 	 
	 
	 	 
	Yock Family Revocable Trust, dated 7/21/93
	 	 
	Paul G. Yock and Cynthia Yock, Trustees
	 	 
	98 Inglewood Lane
	 	 
	Atherton, CA 94027
	 	 
	 
	 	 
	HEWM/VLG Investments LLC
	 	 
	275 Middlefield Road
	 	 
	Menlo Park, CA 94025
	 	 
	 
	 	 
	G&H Partners
	 	 
	155 Constitution Drive
	 	 
	Menlo Park, California 94025
	 	 
	 
	 	 
	GC&H Investments, LLC
	 	 
	101 California Avenue, 5th Floor
	 	 
	San Francisco, CA 94111-5800
	 	 
	 
	 	 
	Intuitive Surgical, Inc.
	 	 
	950 Kifer Road
	 	 
	Sunnyvale, CA 94086
	 	 
	Attention: Chief Financial Officer
	 	 
	 
	Garvie
Family Trust I
	 	 
	Attn: Robert Stuart Garvie III
	 	 
	774 Mays Boulevard
	 	 
	Incline, Village, NV 89451
	 	 
	 
	 	 
	G. L. Cabot Henderson
	 	 
	One Clocktower Place #321
	 	 
	Nashua, NH 03060
	 	 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

 

	 	 	 
	Johnson & Johnson Development Corporation

	 	 
	Attn: Roger Guidi
	 	 
	One Johnson & Johnson Plaza
	 	 
	New Brunswick, NJ 08933
	 	 
	 
	 	 
	Robert W. Cunningham, as trustee of the endoVia Medical Inc. Noteholders’ Liquidating
Trust
	 	 
	Attn: Matthew Louis
	 	 
	c/o Bank of New York
	 	 
	101 Barclay Street, 8W
	 	 
	New York, NY 10286
	 	 
	 
	 	 
	Seaflower Bioventure Fund II, LLC
	 	 
	Attn: Alexander Moot
	 	 
	c/o Seaflower Ventures
	 	 
	1000 Winter Street, Suite 1000
	 	 
	Waltham, MA 02451
	 	 
	 
	 	 
	Seaflower Health & Technology Fund LLC
	 	 
	Attn: Alexander Moot
	 	 
	c/o Seaflower Ventures
	 	 
	1000 Winter Street, Suite 1000
	 	 
	Waltham, MA 02451
	 	 
	 
	 	 
	Don G. Fisher
	 	 
	1600 Pine Cone Circle
	 	 
	P.O. Box 8753
	 	 
	Incline Village, NV 89452
	 	 
	 
	 	 
	George Vujnovich
	 	 
	111 Forest Hill Drive
	 	 
	Clayton, CA 94517
	 	 
	 
	 	 
	Silicon Valley Bank
	 	 
	2400 Geng Road, Suite 200
	 	 
	Palo Alto, CA 94303
	 	 
	 
	 	 

	 	 	 
	Gold Hill Venture Lending LLC
	 	 
	3003 Tasman Drive
	 	 
	Santa Clara, CA 95054
	 	 
	 
	 	 
	Vanguard VII, L.P. 
	 	 
	Vanguard VII-A, L.P.
	 	 
	Vanguard Vii Accredited Affiliates Fund, L.P.
	 	 
	Vanguard VII Qualified Affiliates Fund, L.P.
	 	 
	525 University Avenue
	 	 
	Suite 1200
	 	 
	Palo Alto, CA 94301
	 	 
	 
	 	 
	Phight, LLC
	 	 
	One Bowerman Drive
	 	 
	c/o Nike, Inc.
	 	 
	Beaverton, OR 97005
	 	 
	 
	 	 
	Grant and Jeannette Heidrich, Trustees of the Heidrich Community Property Trust, UDT 10/84
	 	 
	c/o Mayfield
	 	 
	2800 Sand Hill Rd.
	 	 
	Menlo Park, Ca, 94025
	 	 
	 
	 	 
	The Board of Trustees of the Leland Stanford Junior University (DAPER I)
	 	 
	Stanford Management Company
	 	 
	2770 Sand Hill Road
	 	 
	Menlo Park, CA 94025
	 	 
	 
	 	 
	Rahn Group, LLC
	 	 
	5050 Lincoln Drive
	 	 
	#420
	 	 
	Edina, MN 55436
	 	 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

SCHEDULE A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]